AtriCure (ATRC) director Maggie Yuen reports sale of 3,500 shares

Rhea-AI Filing Summary

AtriCure, Inc. director Maggie Yuen reported selling 3,500 shares of Common Stock on August 5, 2026. The shares were sold in multiple trades at prices between $38.37 and $38.43, for a weighted average price of $38.42 per share. Following this transaction, she holds 14,015 shares directly. The Rule 10b5-1 trading plan checkbox was not selected.

Insider Trade Summary

Net Seller: 3,500 shares

Net Sell 1 txn

Insider Yuen Maggie

Role Director

Sold 3,500 shs ($134K)

Type	Security	Shares	Price	Value
Sale	Common Stock F1	3,500	$38.42	$134K

Holdings After Transaction: Common Stock — 14,015 shares (Direct)

Footnotes (1)

1. F1. This transaction was executed in multiple trades at prices ranging from $38.37 to $38.43 per share. The price reported above reflects the weighted average sales price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

Key Figures

Shares sold: 3,500 shares Weighted average sale price: $38.42 per share Sale price range: $38.37-$38.43 per share +1 more

4 metrics

Shares sold 3,500 shares Common Stock sale on 2026-08-05 by director Maggie Yuen

Weighted average sale price $38.42 per share Weighted average price for 3,500 shares sold

Sale price range $38.37-$38.43 per share Multiple trades executed within this price range

Shares owned after sale 14,015 shares Direct holdings following the reported transaction

Key Terms

weighted average sales price, open market or private transaction, non-derivative

3 terms

weighted average sales price financial

"The price reported above reflects the weighted average sales price."

open market or private transaction financial

"transaction_code_description: Sale in open market or private transaction"

non-derivative financial

"The transaction involves Common Stock classified as non-derivative."

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

Available on EDGAR 08/07/2026 - 09:18 AM Accepted by SEC EDGAR 08/07/2026 - 09:18 AM Learn about SEC filing dates

FAQ

What insider transaction did AtriCure (ATRC) director Maggie Yuen report?

Maggie Yuen reported selling 3,500 AtriCure common shares on August 5, 2026 at a weighted average price of $38.42. The sale was executed in multiple trades between $38.37 and $38.43 per share, according to the Form 4 footnote.

At what prices were AtriCure (ATRC) shares sold in Maggie Yuen’s Form 4?

The Form 4 lists a weighted average sale price of $38.42 per share for 3,500 shares. A footnote explains that individual trades were executed at prices ranging from $38.37 to $38.43 per share, with the average reported as the transaction price.

How many AtriCure (ATRC) shares does Maggie Yuen own after this sale?

After selling 3,500 shares, Maggie Yuen directly holds 14,015 AtriCure common shares. This post-transaction holding figure is disclosed in the Form 4 as the total number of shares beneficially owned following the reported transaction in Common Stock.

Was Maggie Yuen’s AtriCure (ATRC) trade reported under a Rule 10b5-1 plan?

The filing’s Rule 10b5-1 trading arrangement checkbox was not selected. This means the reported sale of 3,500 AtriCure shares was not identified in the Form 4 as being executed pursuant to a pre-arranged Rule 10b5-1 trading plan.

What type of security did Maggie Yuen trade in the AtriCure (ATRC) Form 4?

The transaction involves Common Stock categorized as a non-derivative security. The Form 4 describes the code “S” transaction as a sale in open market or private transaction, covering 3,500 shares of AtriCure common stock at a weighted average price of $38.42.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Yuen Maggie

(Last) (First) (Middle)

7555 INNOVATION WAY

(Street)

MASON OHIO 45040-9695

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
AtriCure, Inc. [ ATRC ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
08/05/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	08/05/2026		S		3,500	D	$38.42(1)	14,015	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. This transaction was executed in multiple trades at prices ranging from $38.37 to $38.43 per share. The price reported above reflects the weighted average sales price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

Remarks:

	/s/ Maggie Yuen	08/07/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)